Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response’s stated risks (respiratory depression, overdose/death with crushing or dissolving, accidental ingestion, and alcohol/CNS depressant interactions) are directly supported by the provided FDA label excerpts in Warnings/Precautions (5.2, 5.1, 5.3) and Drug Interactions (7), with no direct contradictions.
Category Scores
Accurate Statements
Serious/life-threatening/fatal respiratory depression has been reported with tapentadol ER and risk is greatest during initiation or after dosage increases.
Supported by label section 5.2.
Overdose/death risk can occur if tapentadol ER tablets are crushed/chewed/dissolved because uncontrolled delivery of tapentadol results.
Supported by label sections 2.1 and 5.1.
Accidental ingestion (including especially by children) can result in respiratory depression and death due to overdose of tapentadol.
Supported by label section 5.2.
Alcohol co-ingestion can increase plasma tapentadol levels and potentially lead to a fatal overdose; patients must not consume alcohol while on therapy.
Supported by label sections 5.3 and 7.
Concomitant use with benzodiazepines and/or other CNS depressants (including alcohol) may result in profound sedation, respiratory depression, coma, and death.
Supported by label section 5.3 and reinforced by 7.
Unsupported Statements
Contradictions
Important Omissions
The label also specifies additional context such as the increased risk for respiratory depression being greatest at initiation/dose increase and additional risk groups (e.g., chronic pulmonary disease or elderly/cachectic/debilitated).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim is an on-label safety warning statement, and the cited elements match the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omissions of some label context (e.g., emphasis on initiation/dose-increase timing and additional respiratory-risk populations), though not necessary to support the core stated risks.
Suggested Improvement
Optionally include that respiratory depression risk is greatest during initiation and after dosage increases, and/or mention the additional respiratory-risk populations described in 5.8 to better mirror the label wording.